Jake Rubens, Flagship Origination Partner and President of Quotient Therapeutics, explains how the company’s somatic genomics platform is interrogating biology to understand how certain cells evolve ability to resist disease and how that translates to vast opportunity for drug discovery. More from Flagship @ JPM2024 here.
Related Companies
- Quotient Therapeutics Founded: 2022
